Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HGFAC | Q04756 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697147 | 0.85 | HGFAC (0.67) | HGFACLMNATDP1KDM4EL3MBTL1 | |
| SCHEMBL19360824 | 0.80 | MAPT (0.59) | HGFACPOLBTDP1KDM4EALOX5 | |
| SCHEMBL19360021 | 0.80 | MAPT (0.59) | HGFACPOLBTDP1KDM4EALOX5 | |
| SCHEMBL5064727 | 0.79 | KMT2A (0.52) | LMNAKDM4EMAPTNPSR1ALDH1A1 | |
| SCHEMBL4030285 | 0.76 | MEN1 (0.61) | LMNAKDM4EL3MBTL1MAPTNPSR1 | |
| SCHEMBL28193616 | 0.76 | HSD17B10 (0.61) | HGFACLMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL70054 | 0.76 | ALOX5 (0.58) | HGFACPOLBLMNATDP1KDM4E | |
| SCHEMBL10712829 | 0.76 | MAPT (0.48) | HGFACPOLBLMNAMAPTNPSR1 | |
| SCHEMBL7186306 | 0.75 | HSD17B10 (0.59) | HGFACLMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL28193618 | 0.75 | HSD17B10 (0.59) | HGFACLMNAMAPTNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| CN-101448840-B | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER SCHERING PHARMA AG (DE) | 2011-12-14 | — | — | CN | disclosed |
| EP-1802633-B1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2001890-B1 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-7750017-B2 | Heterocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-1802633-A1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1799653-A2 | NOVEL HETEROCYCLES | Bayer Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006055268-A2 | PYRIMIDOTHIENOINDAZOLES CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1651652-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006044524-A1 | BENZOTHIENO’2,3-D! PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006023843-A2 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005010008-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | DPYD, TYMP, TPMT | HGFAC 4135/4885POLB 653/4885LMNA 4106/4885 |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | CCNI, TPMT, TYMP | HGFAC 2633/4885POLB 140/4885LMNA 2801/4885 |
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | HGFAC 1442/4885POLB 277/4885LMNA 850/4885 |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | MKI67, PCNA, MYC | HGFAC 1809/4885POLB 170/4885LMNA 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.